2015 AAN Medical Meeting Reporter: Advances in B-Cell and Other Novel Therapeutics in Multiple Sclerosis

This Medical Meeting Reporter will review and analyze data presented at the 67th Annual American Academy of Neurology Meeting. Expert faculty will present results from clinical trials for novel therapeutics in multiple sclerosis. The role of B-cells and integration of B-cell targeted therapies will also be discussed in terms of selecting the most appropriate treatments plans for MS patients. This activity will provide physicians with the most up-to-date information in the field of multiple sclerosis in order to allow for optimal individualized management of their patients.

TARGET AUDIENCE

Neurologists and other healthcare professionals responsible for the diagnosis, treatment or management of patients with multiple sclerosis

EDUCATIONAL OBJECTIVES

Upon completion of this activity, participants will be able to:

  1. Describe the pathophysiology of multiple sclerosis and the role of the B-cell.
  2. Analyze mechanisms of action and clinical trial data for novel therapeutics in multiple sclerosis.
  3. Integrate B-cell targeted therapies into the discussion of therapy selection to help apply the most appropriate treatment plan.

FACULTY

Fred Lublin, MD
Saunders Family Professor of Neurology
Director, Corinne Goldsmith Dickinson Center for MS
Icahn School of Medicine at Mount Sinai
New York, New York

Clyde E. Markowitz, MD
Director, MS Center
Associate Professor, Department of Neurology
University of Pennsylvania, Perelman School of Medicine
Philadelphia, Pennsylvania

 
 

Suhayl S. Dhib-Jalbut, MD
Chairman
Department of Neurology
Professor of Neurology

Rutgers Robert Wood Johnson Medical School
New Brunswick, New Jersey

 

Disclosure of Conflicts of Interest

It is the policy of the Elsevier Office of Continuing Medical Education that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity. 

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Faculty                                  

Relationship Identified With:

Fred Lublin, MD

Consultant/Advisor: Acorda Therapeutics, Inc.; Actelion Pharmaceuticals US, Inc; Akros Pharma, Inc; Bayer HealthCare Pharmaceuticals; BBB technologies; Bigoen Idec; Celgene Corporation; EMD Serono, Inc.; Forward Pharma; Genentech, Inc.; Genzyme Corporation; Hoffmann-La Roche Ltd; MedImmune, LLC; Novartis Pharmaceutical Corporation; Osmotica Pharmaceutical Corp; Questcor/Mallinckrodt; Receptos, Inc.; Sanofi; Teva Neuroscience, Inc.; XenoPort, Inc.

Grant/Research Support: Biogen Idec; Celgene; Genzyme Corporation; National Institutes of Health; National Multiple Sclerosis Society; Novartis Pharmaceuticals Corporation; Sanofi; Teva Neuroscience, Inc; Transparency Life Sciences

Stock Ownership: Cognition Pharmaceuticals, Inc.

Co-Chief Editor: Multiple Sclerosis and Related Diseases

Clyde E. Markowitz, MD

Consultant/Advisor: Acordia; Bayer; Biogen Idec; EMD Serono; Genentech; Novartis; ONO; Roche; Sanofi; Teva Neuroscience, Inc.

Suhayl S. Dhib-Jalbut, MD

Consultant/Advisor: BMS; Genetech; Genzyme; Mallinckrodt; Serono; Teva Neuroscience, Inc

Grant/Research Support: Biogen Idec; Teva Neuroscience, Inc

 

Planners, Managers, ReviewersSandy Breslow; Brynne Hunter; Jacquelyn Valerio; Timothy Hayes, MD, PhD; Kristen Scollon; Emma Gilmartin; Jaimie Kelly; and Bernard Abrams, MD hereby state that they or their spouse/life partner do not have any financial relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months. 

Accreditation Statement 

The Elsevier Office of Continuing Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Co-provided by the Elsevier Office of Continuing Medical Education and AcademicCME.


Course Open Date: May 29, 2015 | Course Expiration Date: May 28, 2016

Credit Designation Statement

The Elsevier Office of Continuing Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditsTM.  Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Financial Support

This activity has been supported by an independent educational grant from Genentech, Inc.

CME INQUIRIES/SPECIAL NEEDS

For all CME inquiries or special needs, please contact elsevierCME@elsevier.com.


Disclosure of Unlabeled Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Elsevier Office of Continuing Medical Education, AcademicCME and Genentech, Inc. do not recommend the use of any agent outside of the labeled indications.

Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Course summary
Course opens: 
05/29/2015
Course expires: 
05/28/2016
Rating: 
5

Available Credit

Accreditation Period

Course opens: 
05/29/2015
Course expires: 
05/28/2016
Please login or register to take this course.